Evolution of enhanced innate immune evasion by SARS-CoV-2.
COVID-19
/ immunology
Coronavirus Nucleocapsid Proteins
/ chemistry
Evolution, Molecular
Humans
Immune Evasion
Immunity, Innate
/ genetics
Interferons
/ immunology
Mitochondrial Precursor Protein Import Complex Proteins
/ metabolism
Phosphoproteins
/ chemistry
Phosphorylation
Proteomics
RNA, Viral
/ genetics
RNA-Seq
SARS-CoV-2
/ classification
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
31
05
2021
accepted:
14
12
2021
pubmed:
24
12
2021
medline:
25
2
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission
Identifiants
pubmed: 34942634
doi: 10.1038/s41586-021-04352-y
pii: 10.1038/s41586-021-04352-y
pmc: PMC8850198
mid: NIHMS1780228
doi:
Substances chimiques
Coronavirus Nucleocapsid Proteins
0
Mitochondrial Precursor Protein Import Complex Proteins
0
Phosphoproteins
0
RNA, Viral
0
TOMM70 protein, human
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
487-495Subventions
Organisme : Wellcome Trust
ID : 223065
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108079
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM141323
Pays : United States
Organisme : Medical Research Council
ID : MR/W005611/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U19 AI135990
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA239333
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM133981
Pays : United States
Organisme : Wellcome Trust
ID : 207511
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P50 AI150476
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143292
Pays : United States
Organisme : Wellcome Trust
ID : 206298
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U54 CA260560
Pays : United States
Organisme : Wellcome Trust
ID : 207498
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI120694
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135972
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI063302
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266–269 (2021).
doi: 10.1038/s41586-021-03470-x
pubmed: 33767447
Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 eabg3055 (2021).
pubmed: 33658326
pmcid: 8128288
doi: 10.1126/science.abg3055
Galloway, S. E. et al. Emergence of SARS-CoV-2 B.1.1.7 lineage—United States, December 29, 2020–January 12, 2021. MMWR Morb. Mortal. Wkly Rep. 70, 95–99 (2021).
pubmed: 33476315
pmcid: 7821772
doi: 10.15585/mmwr.mm7003e2
Calistri, P. et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int. J. Infect. Dis. 105, 753–755 (2021).
pubmed: 33684558
pmcid: 7934691
doi: 10.1016/j.ijid.2021.03.005
Foster, T. L. et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 20, 429–442 (2016).
pubmed: 27640936
pmcid: 5075283
doi: 10.1016/j.chom.2016.08.006
Gondim, M. V. P. et al. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Sci. Transl. Med. 13, eabd8179 (2021).
pubmed: 33441429
pmcid: 7923595
doi: 10.1126/scitranslmed.abd8179
Sumner, R. P. et al. Are evolution and the intracellular innate immune system key determinants in HIV transmission? Front. Immunol. 8, 1246 (2017).
pubmed: 29056936
pmcid: 5635324
doi: 10.3389/fimmu.2017.01246
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
pubmed: 32972995
pmcid: 7857407
doi: 10.1126/science.abd4570
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
pubmed: 32972996
pmcid: 7857397
doi: 10.1126/science.abd4585
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).
doi: 10.1038/s41586-020-03065-y
pubmed: 33307546
Thorne, L. G. et al. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 40, e107826 (2021).
pubmed: 34101213
pmcid: 8209947
doi: 10.15252/embj.2021107826
Lei, X. et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 11, 3810 (2020).
pubmed: 32733001
pmcid: 7392898
doi: 10.1038/s41467-020-17665-9
Miorin, L. et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl Acad. Sci. USA 117, 28344–28354 (2020).
pubmed: 33097660
pmcid: 7668094
doi: 10.1073/pnas.2016650117
Hackbart, M., Deng, X. & Baker, S. C. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl Acad. Sci. USA 117, 8094–8103 (2020).
pubmed: 32198201
pmcid: 7149396
doi: 10.1073/pnas.1921485117
Ferrarini, M. G. et al. Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis. Commun. Biol. 4, 590 (2021).
pubmed: 34002013
pmcid: 8128904
doi: 10.1038/s42003-021-02095-0
Sorek, M., Meshorer, E. & Schlesinger, S. Transposable elements as sensors of SARS-CoV-2 infection. Preprint at https://doi.org/10.1101/2021.02.25.432821 (2021).
Rookhuizen, D. C., Bonte, P. E., Ye, M., Hoyler, T. & Gentili, M. Induction of transposable element expression is central to innate sensing. Preprint at https://doi.org/10.1101/2021.09.10.457789 (2021).
Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).
pubmed: 33243994
pmcid: 7693302
doi: 10.1038/s41467-020-19808-4
Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).
pubmed: 33184236
pmcid: 7775736
doi: 10.1126/science.abe8499
Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021).
doi: 10.1038/s41586-020-2895-3
pubmed: 33106671
Volz, E. et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 184, 64–75 (2021).
pubmed: 33275900
pmcid: 7674007
doi: 10.1016/j.cell.2020.11.020
Ozono, S. et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 12, 848 (2021).
pubmed: 33558493
pmcid: 7870668
doi: 10.1038/s41467-021-21118-2
Guo, K., Barrett, B. S., Mickens, K. L., Hasenkrug, K. J. & Santiago, M. L. Interferon resistance of emerging SARS-CoV-2 variants. Preprint at https://doi.org/10.1101/2021.03.20.436257 (2021).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Liu, H. et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95–102 (2019).
doi: 10.1038/s41591-018-0302-5
pubmed: 30559422
Ochoa, D. et al. An atlas of human kinase regulation. Mol. Syst. Biol. 12, 888 (2016).
pubmed: 27909043
pmcid: 5199121
doi: 10.15252/msb.20167295
Hernandez-Armenta, C., Ochoa, D., Gonçalves, E., Saez-Rodriguez, J. & Beltrao, P. Benchmarking substrate-based kinase activity inference using phosphoproteomic data. Bioinformatics 33, 1845–1851 (2017).
pubmed: 28200105
pmcid: 5870625
doi: 10.1093/bioinformatics/btx082
Clark, K., Plater, L., Peggie, M. & Cohen, P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IκB kinase ε. J. Biol. Chem. 284, 14136–14146 (2009).
pubmed: 19307177
pmcid: 2682862
doi: 10.1074/jbc.M109.000414
Heo, J.-M. et al. RAB7A phosphorylation by TBK1 promotes mitophagy via the PINK–PARKIN pathway. Sci. Adv. 4, eaav0443 (2018).
pubmed: 30627666
pmcid: 6314648
doi: 10.1126/sciadv.aav0443
Jungreis, I. et al. Conflicting and ambiguous names of overlapping ORFs in the SARS-CoV-2 genome: a homology-based resolution. Virology 558, 145–151 (2021).
doi: 10.1016/j.virol.2021.02.013
pubmed: 33774510
Parker, M. D., Lindsey, B. B., Shah, D. R., Hsu, S. & Keeley, A. J. Altered sub-genomic RNA expression in SARS-CoV-2 B. 1.1. 7 infections. Preprint at https://doi.org/10.1101/2021.03.02.433156 (2021).
Jungreis, I., Sealfon, R. & Kellis, M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 12, 2642 (2021).
pubmed: 33976134
pmcid: 8113528
doi: 10.1038/s41467-021-22905-7
Oh, S. J. & Shin, O. S. SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response. Cells 10, 530 (2021).
pubmed: 33801464
pmcid: 7999926
doi: 10.3390/cells10030530
Schmidt, N. Novel functions of host TRIM28 in restricting influenza virus infections. Dissertation, University of Zurich (2019).
Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468 (2020).
pubmed: 32353859
pmcid: 7431030
doi: 10.1038/s41586-020-2286-9
Liu, X.-Y., Wei, B., Shi, H.-X., Shan, Y.-F. & Wang, C. Tom70 mediates activation of interferon regulatory factor 3 on mitochondria. Cell Res. 20, 994–1011 (2010).
doi: 10.1038/cr.2010.103
pubmed: 20628368
Jiang, H.-W. et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell. Mol. Immunol. 17, 998–1000 (2020).
pubmed: 32728199
doi: 10.1038/s41423-020-0514-8
Gao, X. et al. Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus–host interactions. Nat. Commun. 12, 2843 (2021).
pubmed: 33990585
pmcid: 8121815
doi: 10.1038/s41467-021-23118-8
Bouhaddou, M. et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell 182, 685–712 (2020).
pubmed: 32645325
pmcid: 7321036
doi: 10.1016/j.cell.2020.06.034
Gordon, D. E. et al. Comparative host–coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370, eabe9403 (2020).
pubmed: 33060197
pmcid: 7808408
doi: 10.1126/science.abe9403
Calistri, P. et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int. J. Infect. Dis. 105, 753–755 (2021).
pubmed: 33684558
pmcid: 7934691
doi: 10.1016/j.ijid.2021.03.005
Kissler, S. M. et al. Densely sampled viral trajectories suggest longer duration of acute infection with B. 1.1. 7 variant relative to non-B. 1.1. 7 SARS-CoV-2. Preprint at https://doi.org/10.1101/2021.02.16.21251535 (2021).
Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270–274 (2021).
pubmed: 33723411
doi: 10.1038/s41586-021-03426-1
Scientific Advisory Group for Emergencies. NERVTAG: Update Note on B.1.1.7 Severity. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982640/Feb_NERVTAG_update_note_on_B.1.1.7_severity.pdf (2021).
Sekizuka, T. et al. Genome recombination between Delta and Alpha variants of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Preprint at https://doi.org/10.1101/2021.10.11.21264606 (2021).
Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature https://doi.org/10.1038/s41586-021-04266-9 (2021).
Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119 (2021).
pubmed: 34488225
pmcid: 8566220
doi: 10.1038/s41586-021-03944-y
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
doi: 10.1038/s41586-021-03777-9
pubmed: 34237773
Escalera, A. et al. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage. Preprint at https://doi.org/10.1101/2021.08.05.455290 (2021).
Gribble, J. et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 17, e1009226 (2021).
pubmed: 33465137
pmcid: 7846108
doi: 10.1371/journal.ppat.1009226
Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956–963 (2020).
pubmed: 32540903
pmcid: 7299280
doi: 10.1126/science.abc7520
Thorne, L. G., Reuschl, A. K. & Zuliani-Alvarez, L. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 40, e107826 (2020).
Rheinwald, J. G. & Green, H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331–343 (1975).
doi: 10.1016/S0092-8674(75)80001-8
pubmed: 1052771
Brown, J. C. et al. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape. Preprint at https://doi.org/10.1101/2021.02.24.432576 (2021).
Meredith, L. W. et al. Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study. Lancet Infect. Dis. 20, 1263–1271 (2020).
pubmed: 32679081
pmcid: 7806511
doi: 10.1016/S1473-3099(20)30562-4
Tyson, J. R. et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. Preprint at https://doi.org/10.1101/2020.09.04.283077 (2020).
Lindenbach, B. D. Measuring HCV infectivity produced in cell culture and in vivo. Methods Mol. Biol. 510, 329–336 (2009).
doi: 10.1007/978-1-59745-394-3_24
pubmed: 19009272
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT–PCR. Eurosurveillance 25, 23 (2020).
Thao, T. T. N. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582, 561–565 (2020)
doi: 10.1038/s41586-020-2294-9
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772
doi: 10.1038/nmeth.2019
Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).
pubmed: 17076895
pmcid: 1794559
doi: 10.1186/gb-2006-7-10-r100
Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907–915 (2019).
pubmed: 31375807
pmcid: 7605509
doi: 10.1038/s41587-019-0201-4
Kovaka, S. et al. Transcriptome assembly from long-read RNA-seq alignments with StringTie2. Genome Biol. 20, 278 (2019).
pubmed: 31842956
pmcid: 6912988
doi: 10.1186/s13059-019-1910-1
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Bachman, J. A., Gyori, B. M. & Sorger, P. K. Assembling a phosphoproteomic knowledge base using ProtMapper to normalize phosphosite information from databases and text mining. Preprint at https://doi.org/10.1101/822668 (2019).
Casado, P. et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal. 6, rs6 (2013).
doi: 10.1126/scisignal.2003573
pubmed: 23532336
Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363–1375 (2019).
pubmed: 31340985
pmcid: 6673718
doi: 10.1101/gr.240663.118
Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838–847 (2016).
pubmed: 27322546
pmcid: 5040167
doi: 10.1038/ng.3593